Clinical Trial Update: Panzyga in CIDP Administered at Different Infusion Rates [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update evaluating Panzyga for chronic inflammatory demyelinating polyneuropathy at different infusion rates.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyneuropathy

Drugs mentioned

• Panzyga (intravenous immunoglobulin)

Snippet

Sponsor: Vera Bril | Conditions: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Phase 3 | Status: UNKNOWN